All posts by Jayant Vaidya

Worldwide adoption of TARGeted Intraoperative radioTHerapy TARGIT IORT for breast cancer

After publication of the results of the TARGIT-A trial results, TARGIT IORT has been increasingly used around the world.
It is currently available in over 300 centres in all five continents.
In the summer of 2015, when 250 centres were offering TARGIT IORT, a survey was prepared, sent out and analysed with the help of Uma Vaidya and Lilly Bao to these centres.
The figure below gives the data from about half of these centres who had replied to the survey by October 2015.
By October 2015, 125 of the 250 centres had responded to our query ‘how many patients have you treated with TARGIT IORT?’.
The total number of patients treated in these 125 centres was 11740.
Thus it is reasonable to say that about 20,000 patients have been already treated around the world with this approach.

Screenshot 2015-10-22 18.40.32

World map of countries where breast cancer centres offer TARGIT IORT with Intrabeam 2016
World map of countries where breast cancer centres offer TARGIT IORT with Intrabeam 2016

TARGIT IORT news in Summer 2015

The Wall Street Journal, 25 Aug 2015 features TARGIT IORT for breast cancer

The main article: Alternative Way to Treat Early-Stage Breast Cancer With Radiation TARGIT-IORT-featured-in-The-Wall-Street-Journal-25-August-2015.pdf

The author Melinda Becks explains in a video interview below New Thinking on Radiation for Breast Cancer Treatment.

The West Australian: Breast Cancer Breakthrough- Revolution in radiotherapy , 31 August 2015

Christobel SaundersFrom 1 September 2015, women with breast cancer in Australia can now get access to Medicare-funded TARGIT IORT 

TARGIT-A trial of IORT for breast cancer – Adequate follow up for a large number of patients.

Click to access the PDF file: Adequacy of follow up duration in TARGIT-A trial of targeted intraoperative radiotherapy for breast cancer

Adequacy of follow up duration in the TARGIT-A trial 

In this short paper, we provide a detailed explanation about the follow-up of the TARGIT-A trial[1, 2] and clarify how it is long enough to be relied upon to guide the application of TARGIT using Intrabeam in routine clinical practice in appropriate patients. We have explained this in the correspondence columns of the Lancet (17 May 2014)

It may appear tempting to speculate that years in the future a difference in local recurrence will become apparent and the difference in mortality that we have already seen will go away, but neither our data nor previous trial results support this speculation, which ignores our understanding about the complex natural history of breast cancer and robust literature about the toxic effects of EBRT on other organs such as the heart.

Continuing to ignore the TARGIT-A trial data can potentially put a large proportion of breast cancer patients at a significant disadvantage. Continue reading TARGIT-A trial of IORT for breast cancer – Adequate follow up for a large number of patients.